197 related articles for article (PubMed ID: 24736070)
1. Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.
Isobe K; Hata Y; Tochigi N; Kaburaki K; Kobayashi H; Makino T; Otsuka H; Sato F; Ishida F; Kikuchi N; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Iyoda A; Homma S
J Thorac Oncol; 2014 Apr; 9(4):483-7. PubMed ID: 24736070
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
[TBL] [Abstract][Full Text] [Related]
3. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
4. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
[TBL] [Abstract][Full Text] [Related]
5. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.
Nie W; Tao X; Wei H; Chen WS; Li B
Oncotarget; 2015 Sep; 6(28):25696-700. PubMed ID: 26325082
[TBL] [Abstract][Full Text] [Related]
6. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Corrales-Rodriguez L; Martín C; Reguart N; Archila P; Rodríguez J; Cuello M; Ortíz C; Franco S; Rolfo C; Rosell R; on behalf of the CLICaP
Oncotarget; 2016 Sep; 7(42):68933-68942. PubMed ID: 27926478
[TBL] [Abstract][Full Text] [Related]
7. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor].
Zheng L; Lin B; Song Z; Xie F; Hong W; Feng J; Shao L; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):632-8. PubMed ID: 24345487
[TBL] [Abstract][Full Text] [Related]
9. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
[TBL] [Abstract][Full Text] [Related]
10. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
Cardona AF; Ordóñez-Reyes C; Ruiz-Patiño A; Garcia-Robledo JE; Barron LZ; Recondo G; Rojas L; Corrales L; Martín C; Barrón F; Sotelo C; Rodríguez J; Ricaurte L; Rolfo C; Ávila J; Mayorga D; Archila P; Otero J; Mas L; Bermudez M; Gamez T; Carranza H; Vargas C; Rosell R; Arrieta O
JCO Precis Oncol; 2021 Nov; 5():839-848. PubMed ID: 34994616
[TBL] [Abstract][Full Text] [Related]
11. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
[TBL] [Abstract][Full Text] [Related]
12. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
13. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
[TBL] [Abstract][Full Text] [Related]
14. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.
Lv F; Sun L; Yang Q; Pan Z; Zhang Y
Biomed Res Int; 2021; 2021():3621828. PubMed ID: 34722761
[TBL] [Abstract][Full Text] [Related]
16. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
17. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.
Ebi H; Oze I; Nakagawa T; Ito H; Hosono S; Matsuda F; Takahashi M; Takeuchi S; Sakao Y; Hida T; Faber AC; Tanaka H; Yatabe Y; Mitsudomi T; Yano S; Matsuo K
J Thorac Oncol; 2015 Jan; 10(1):59-66. PubMed ID: 25384174
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma].
Qian K; Zhang Y; Zhi X
Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):543-548. PubMed ID: 28855035
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
